



AEGIRBIO UK LTD AND UNDISCLOSED PARTNER SIGN LOI TO DEVELOP INNOVATIVE DIGITAL DIAGNOSTIC PRODUCT

Aegirbio UK Ltd, a subsidiary of Magnasense AB, has signed a Letter of Intent (LOI) with an undisclosed partner to jointly develop and supply a next-generation saliva based digital diagnostic product for professional use, aimed at monitoring health related problems. The partner has deliberately chosen not to take a leading role in the development process and does not intend to publicly disclose strategic details, to avoid offering insights that could benefit competitors.

This collaboration brings together Aegirbio's expertise in advanced diagnostics and digital health technology with the partner's strong market position and regulatory know-how.

Under the planned agreement, Aegirbio UK Ltd will lead the design, development, and validation of a cutting-edge diagnostic system—including a reusable magnetic reader, single-use cartridge, sample collection tools, and a cloud-connected software platform.

Following successful development, Aegirbio UK Ltd will also assume responsibility for manufacturing through a subcontracting model. The partner will provide milestone-based development funding and overseeing regulatory approvals and import licensing.

The LOI outlines both parties' intention to finalize a formal agreement in 2025 and includes key provisions regarding intellectual property rights, exclusivity, technology transfer, and long-term business continuity.

Quotes:

"This LOI marks a significant milestone for Aegirbio UK as we expand our presence in the professional diagnostics space," said Marco Witteveen, CEO of Aegirbio UK Ltd. "We are proud to collaborate with a trusted industry leader to bring innovative digital tools to market."

About Aegirbio UK Ltd

Aegirbio UK Ltd is a subsidiary of Magnasense AB, a Swedish diagnostics company specializing in advanced point-of-care solutions and digital health platforms.

For additional information, please contact:

Marco Witteveen, CEO, Magnasense AB

Email: ir@magnasense.com

The Company's Certified Adviser is Eminova Fondkommission AB | adviser@eminova.se

**About Magnasense AB**

Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, Magnasense was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Magnasense's website www.magnasense.com.